Monitoring the brain with MRI to detect cancer spread early

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research aims to determine if regular brain MRI surveillance after radiation therapy can help identify brain metastases in patients with non-squamous stage III nonsmall cell lung cancer before they become symptomatic. The primary objective is to compare the rate of symptomatic brain metastasis presentation in patients undergoing additional MRI follow-ups to historical controls. Secondary objectives include estimating the time to brain failure and documenting the characteristics of brain metastases in these patients. Participants will undergo MRI scans and blood sample collection, with follow-up lasting approximately 780 days.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years of age.
* Patients with non-squamous locally advanced lung cancer defined by American Joint Committee on Cancer (AJCC) version 8 stage IIIA, IIIB, or IIIC disease.
* Histology described as adeno-squamous or not otherwise specified favoring squamous are eligible.
* Patients may be enrolled before or after the start of radiation therapy but must be enrolled and have their first surveillance MRI brain at 120 +/- 10 days of their first treatment of radiation therapy for their locally advanced lung cancer. The first radiation treatment is defined as day 1.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3.
* Epidermal growth factor receptor (EGFR) \> 30 mL/min/1.73m2.
* Patients must be eligible for a brain MRI per the Wake Forest MRI safety screening checklist questionnaire. This will be completed by a MRI imaging technician, enrolling physician, CPDM staff member, a magnetic resonance safety officer, and/or a radiologist as indicated in the form.

Exclusion Criteria:

* Known brain metastases on staging MRI.
* Questionable findings that may represent a differential of vasculature abnormalities/stroke/ and or metastatic disease with recommended short interval follow-up are not an exclusion factor for study participation. The recommended follow-up imaging for such findings should have no bearing on the imaging schedule in this protocol, and this research protocol imaging should NOT serve as an official follow-up scan for such findings.
* Patients who are pregnant or breastfeeding.
* Premenopausal persons of childbearing potential must have a negative pregnancy test within 14 days of enrollment. If women are not of childbearing potential as defined by women who are menopausal female or has had a hysterectomy, bilateral oophorectomy, or medically-documented ovarian failure, they will not require a pregnancy test. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

Where it's running

• Wake Forest Baptist Comprehensive Cancer Center
  Winston-Salem, North Carolina, United States Recruiting

Study contacts

• Principal investigator: Michael Farris, MD — Wake Forest Baptist Comprehensive Cancer Center
• Study coordinator: Deonna Asbury
• Email: Deonna.Asbury@advocatehealth.org
• Phone: +13367137749

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• EarlyFDG PET after Radiotherapy to See Brain Metastases and Radionecrosis

  This study tests whether a short FDG-PET scan after radiotherapy can help tell apart radionecrosis from recurring brain metastases in adults.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens · NCT07632092

• IL-8 receptor–modified CAR T cells for brain metastases in adults

  This phase 1 study tests whether patient-derived, IL-8 receptor–modified CD70 CAR T cells can be safely given to adults with brain metastases.

  Recruiting Phase 1 University of Florida · Gainesville, Florida · NCT07569263

• Targeted FSRT plus bevacizumab versus hippocampus-sparing whole-brain radiation for people with lung adenocarcinoma that has spread to the brain

  This will test whether focused 5-day fractionated stereotactic radiotherapy (FSRT) combined with bevacizumab works better than hippocampus-avoidant whole-brain radiotherapy with a simultaneous boost at controlling brain metastases and protecting memory in adults with lung adenocarcinoma and extensive brain metastases.

  Recruiting at 3 sites Phase 3 Sun Yat-sen University · Chongqing, Chongqing Municipality and 2 other locations · NCT07481786

• Molecular comparison of primary gastroesophageal cancers and their brain metastases

  This project will test whether key biomarkers (HER2, MSI, PD-L1, CLDN18.2) match between primary gastroesophageal tumors and their matched brain metastases using archived tissue.

  Recruiting Blokhin's Russian Cancer Research Center · Moscow · NCT07464470

• Imaging inflammation in primary and metastatic brain tumors with [C-11]-CS1P1 PET

  This trial will test a new PET tracer, [C-11]-CS1P1, in adults with primary or secondary brain tumors to see if tracer patterns of inflammation relate to MRI, treatments, and clinical outcomes.

  Recruiting Phase 2 Washington University School of Medicine · St Louis, Missouri · NCT07462507

• Cognitive stepped care program for adults with brain metastases

  This project will test whether routine screening plus a stepped program of education and tailored cognitive support can help adults with brain metastases manage thinking and memory problems.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07355348

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.